The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients

Lung Cancer

Volumn 22, Issue 3, 1998, Pages 181-190

  Kim, Young Chul ^a   Park, Kyung Ok ^a   Kern, Jeffrey A ^b   Park, Chang Soo ^a   Lim, Sung Chul ^a   Jang, An Soo ^a   Yang, Jae Beom ^a  

^a Chonnam National University Medical School   (South Korea)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Bcl 2; HER2; Immunohistochemistry; Lung neoplasm; Oncogenes; P53; Ras

Indexed keywords

GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN P53; RAS PROTEIN;

ADENOCARCINOMA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KOREA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KOREA; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032430664     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(98)00086-5     Document Type: Article

References (32)

1. Lee SI, Gark HG, Ahn OH, Park CY, Ko JO, Seo CI, Hur YS, Seo KA. Korean Cancer Patients Registry Report (1993.1.1-1993.12.3), p. 18, Seoul, Ministry of Health and Welfare, Republic of Korea, 1996.
2. Devesa S.S., Blot W.J., Stone B.J., Miller B.A., Tarone R.E., Fraumeni J.F. Jr Recent cancer trends in the United States. J Natl Cancer Inst. 87:1995;175-182.
3. Travis W.D., Lubin J., Ries L., Devesa S. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer. 77:1996;2464-2470.
4. Kern J.A., Schwartz D.A., Nordberg J.E., Weiner D.B., Greene M.I., Torney L., Robinson R.A. p185neu Expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 50:1990;5184-5187.
5. Harpole D.H. Jr, Herndon J., Wolfe W.G., Iglehart J.D., Marks J.R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 55:1995;51-56.
6. Weiner D.B., Nordberg J., Robinson R., Nowell P.C., Gazdar A., Greene M.I., Williams W.V., Cohen J.A., Kern J.A. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res. 50:1990;421-425.
7. Shi D., He G., Cao S., Pan W., Zhang H.Z., Yu D., Hung M.C. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol Carcinog. 5:1992;213-218.
8. Tateishi M., Ishida T., Mitsudomi T., Kaneko S., Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer. 27:1991;1372-1375.
9. Slebos R.J., Kibbelaar R.E., Dalesio O., Kooistra A., Stam J., Meijer C.J., Wagenaar S.S., Vanderschueren R.G., van Zandwijk N., Mooi W.J. et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. New Engl J Med. 323:1990;561-565.
10. Sugio K., Ishida T., Yokoyama H., Inoue T., Sugimachi K., Sasazuki T. ras Gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res. 52:1992;2903-2906.
11. Kern J.A., Slebos R.J., Top B., Rodenhuis S., Lager D., Robinson R.A., Weiner D., Schwartz D.A. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest. 93:1994;516-520.
12. Miyamoto H., Harada M., Isobe H., Akita H.D., Haneda H., Yamaguchi E., Kuzumaki N., Kawakami Y. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res. 51:1991;6346-6350.
13. McLaren R., Kuzu I., Dunnill M., Harris A., Lane D., Gatter K.C. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer. 66:1992;735-738.
14. Ebina M., Steinberg S.M., Mulshine J.L., Linnoila R.I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 54:1994;2496-2503.
15. Lee J.S., Yoon A., Kalapurakal S.K., Ro J.Y., Lee J.J., Tu N., Hittelman W.N., Hong W.K. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol. 13:1995;1893-1903.
16. Korsmeyer S.J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 80:1992;879-886.
17. Pezzella F., Turley H., Kuzu I., Tungekar M.F., Dunnill M.S., Pierce C.B., Harris A., Gatter K.C., Mason D.Y. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med. 329:1993;690-964.
18. Fontanini G., Vignati S., Bigini D., Mussi A., Lucchi M., Angeletti C.A., Basolo F., Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer. 71:1995;1003-1007.
19. Walker C., Robertson L., Myskow M., Dixon G. Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. Br J Cancer. 72:1995;164-169.
20. Gaffney E.F., Aj O.N., Staunton M.J. bcl-2 and prognosis in non-small-cell lung carcinoma. N Engl J Med. 330:1994;1757-1758.
21. Boise L.H., Gottschalk A.R., Quintans J., Thompson C.B. Bcl-2 and Bcl-2-related proteins in apoptosis regulation. Curr Top Microbiol Immunol. 200:1995;107-121.
22. Kim Y.C., Park K.O., Kim H.J., Choi I.S., Park C.S., Juhng S.W. DNA ploidy and proliferative activity in bcl-2 expressed non-small cell lung cancer. Korean J Intern Med. 11:1996;101-107.
23. Mountain C.F. The new International Staging System for Lung Cancer. Surg Clin North Am. 67:1987;925-935.
24. Reed J.A., Manahan L.J., Park C.S., Brigati D.J. Complete one-hour immunocytochemistry based on capillary action. Biotechniques. 13:1992;434-443.
25. Guesdon J.L., Ternynck T., Avrameas S. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem. 27:1979;1131-1139.
26. Harada M., Dosaka-Akita H., Miyamoto H., Kuzumaki N., Kawakami Y. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer. 69:1992;72-77.
27. Pezzella F., Tse A.G., Cordell J.L., Pulford K.A., Gatter K.C., Mason D.Y. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol. 137:1990;225-232.
28. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 38:1984;511.
29. Cox D.R., Oakes D. Analysis of survival data. 1984;Chapman and Hall, New York.
30. Choi J.H., Chung H.C., Yoo N.C., Lee H.R., Lee K.H., Choi W., Lim H.Y., Koh E.H., Kim J.H., Roh J.K. et al. Changing trends in histologic types of lung cancer during the last decade (1981-1990) in Korea: a hospital-based study. Lung Cancer. 10:1994;287-296.
31. Xu H.J., Quinlan D.C., Davidson A.G., Hu S.X., Summers C.L., Li J., Benedict W.F. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst. 86:1994;695-699.
32. Marchetti A., Buttitta F., Merlo G., Diella F., Pellegrini S., Pepe S., Macchiarini P., Chella A., Angeletti C.A., Callahan R. et al. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res. 53:1993;2846-2851.